Nervous System Lysosomal Storage Diseases

This is a group of rare genetic disorders. They happen when the body can't break down certain substances properly. These substances build up inside tiny parts of cells called lysosomes. This buildup can cause problems in different parts of the body, including the brain and nerves.

Condition

What people with Nervous System Lysosomal Storage Diseases report

Every report comes from a Lived member, sent anonymously.

Have you tried Enzyme Replacement Therapy for Nervous System Lysosomal Storage Diseases?

NameHow it went

About Nervous System Lysosomal Storage Diseases

What It Is

Nervous system lysosomal storage diseases are a group of rare inherited disorders in which the brain and nerves are damaged by material that cells cannot break down. Lysosomes are small compartments inside cells that digest and recycle used fats, sugars and proteins. When one of the enzymes or other proteins they depend on is missing or does not work, undigested material builds up inside the cells (the "storage" in the name) and gradually harms nerve cells. This is an umbrella term rather than a single disease. It includes Tay-Sachs disease, Niemann-Pick disease type C, Krabbe disease, metachromatic leukodystrophy (MLD), the Batten diseases (also called neuronal ceroid lipofuscinoses) and some mucopolysaccharidoses (MPS), such as Hurler, Hunter and Sanfilippo syndromes. Many of these diseases also affect the liver, spleen, bones or other organs. Each one is rare, but taken together, lysosomal storage diseases affect about 1 in 5,000 babies. Most of these diseases begin in infancy or childhood, although some forms start in adulthood, and most get worse over time. Common effects include losing skills a child had already gained, seizures, changes in muscle tone and movement, difficulty with speech and swallowing, and loss of vision or hearing. Which of these appear, and how quickly, depends on the specific disease.

Causes & Risk Factors

Each of these diseases is caused by a change in a single gene that a person is born with. They are not caused by infection, diet or anything that happened during pregnancy. Most are inherited in an autosomal recessive pattern, meaning a child is affected only when they receive a nonworking copy of the same gene from both parents. Parents who each carry one copy usually have no symptoms and often no known family history. When both parents are carriers, each pregnancy has a 25% (one in four) chance of producing an affected child. Some of these genetic changes are more common in particular communities; the Tay-Sachs gene change, for example, is most common among people of Eastern European Ashkenazi Jewish ancestry. A few types follow a different pattern. Hunter syndrome (MPS II) is X-linked: the gene sits on the X chromosome, so it affects boys far more often than girls, and a father cannot pass it to his son.

How It's Diagnosed

Diagnosis often begins when a child stops gaining new skills or starts losing them, or when an adult develops unexplained, worsening problems with movement, thinking or behavior. Because these diseases are rare and early signs can resemble more common conditions, families sometimes wait a long time for an answer. An assessment usually includes a detailed history (including family history), a physical and neurological examination, and brain imaging such as magnetic resonance imaging (MRI). Imaging can show whether the white matter is affected; white matter is the brain's wiring, the nerve fibers and their fatty insulation (myelin) that carry signals between nerve cells. Laboratory tests, often a blood test that measures how well the suspected missing enzyme works, and genetic testing then identify the exact disease. Knowing the precise type matters because the treatment options, and the time window in which they can help, differ from one disease to the next. Newborn screening blood tests now check for some of these diseases, which can allow treatment to start before symptoms appear. Once a family's genetic change is known, brothers and sisters can be tested, relatives can find out whether they are carriers, and testing is available during a future pregnancy.

Treatment Options

Treatment depends on the specific disease and on how far it has progressed. For many types there is still no treatment that changes the course of the disease. Care then focuses on symptoms and quality of life: medicines to control seizures and muscle stiffness, physical, occupational and speech therapy, and nutrition support, which may include a feeding tube when swallowing becomes difficult. Reaching the brain is the central challenge. Enzyme replacement therapy, a regular infusion of the missing enzyme into a vein, helps body symptoms in several lysosomal diseases, but the enzyme does not cross into the brain in useful amounts, so it does little for nerve damage. The disease-specific treatments that do help the nervous system work around that barrier, and each applies only to particular diseases and ages. Cerliponase alfa (Brineura) is a replacement enzyme for CLN2 disease (named for the CLN2 gene), one form of Batten disease. It is infused directly into the fluid-filled spaces of the brain every other week through a surgically implanted device, and it slows the loss of walking in children. The device carries a risk of infection, including meningitis. A stem cell transplant from a healthy donor can provide a lasting source of the missing enzyme, including in the brain. It is an established option for Krabbe disease, for severe MPS I (Hurler syndrome) in children younger than about two and a half, and for selected people with MLD or Hunter syndrome. Because the donor cells take 12 to 18 months to have their full effect in the brain, transplant helps only when it is done before symptoms start or very early; in early infantile Krabbe disease, ideally within the first months of life. Even then, many children are left with some lasting problems. Transplant requires chemotherapy beforehand and carries serious risks, including infection, failure of the donor cells to take hold, and graft-versus-host disease, in which donor immune cells attack the body. For MLD, atidarsagene autotemcel (Lenmeldy) is a one-time gene therapy for children with certain late infantile or early juvenile forms who have no symptoms yet or, in the early juvenile form, only early symptoms. The child's own stem cells are collected, given a working copy of the gene in a laboratory and returned after high-dose chemotherapy. For Niemann-Pick disease type C, two medicines were approved in the United States in 2024 to treat its neurological effects: arimoclomol (Miplyffa), for people aged 2 and older, taken together with miglustat, an oral medicine that reduces how much of the stored fatty material the body makes, and levacetylleucine (Aqneursa), for adults and children who weigh at least 15 kilograms (about 33 pounds). Miglustat's benefit is established in this disease, but controlled studies in several other types, including late-onset Tay-Sachs disease and Sanfilippo syndrome, did not show it improved neurological symptoms. A treatment that works in one of these diseases cannot be assumed to work in another. Newer gene therapies and enzymes designed to cross into the brain are being studied, but most remain experimental.

What to Expect

The outlook varies enormously from one disease to another. The infant forms are often the most severe. In classic Tay-Sachs disease, for example, a baby seems to develop normally for the first few months, then gradually loses abilities, including vision, hearing and swallowing, and even with the best care children usually die by about age 4. Forms that begin later in childhood or in adulthood follow their own courses, and a specialist familiar with the specific type can describe what is likely. As most of these diseases progress, needs change. Families may need help with feeding, mobility equipment, seizure control, communication, school support and, eventually, round-the-clock care. Care usually involves a team that can include a neurologist, a metabolic or genetics specialist, therapists, a dietitian and palliative care, which focuses on comfort and quality of life and can work alongside other treatment. For children who receive transplant, gene therapy or enzyme treatment, regular follow-up tracks development, movement and the effects of treatment over years. These treatments can slow or limit the disease, but they rarely prevent all of its effects. Caring for a child with a progressive illness is demanding, and genetic counseling, respite care and connection with disease-specific family organizations can help families plan and cope.

When to Seek Help

Arrange an evaluation when a baby or child stops gaining new skills or loses ones they had, or has unexplained problems with movement, muscle tone, vision, hearing or behavior, especially if a relative has one of these diseases. An adult with steadily worsening problems with balance, speech, thinking or mood that have no clear cause also deserves a neurological assessment. If a newborn screening result flags one of these diseases, follow up with the specialist team without delay, because some treatments only help if they start before symptoms appear. Families who know they carry one of these gene changes can ask for genetic counseling before a future pregnancy. For someone already diagnosed, contact the care team promptly about new or more frequent seizures, coughing or choking during meals, weight loss, or breathing that is gradually becoming harder. Call 911 for a seizure that lasts longer than 5 minutes or is followed by another before the person recovers (unless their seizure action plan gives a different step), or for breathing difficulty that comes on suddenly or is severe. For a child with an implanted device for brain infusions, call the team right away about redness, swelling or fluid leaking at the scalp site, or a fever.

Questions to Ask Your Doctor

  1. 1.Which specific disease is this, and what does that tell us about how it is likely to progress?
  2. 2.Are there treatments, including transplant, gene therapy or clinical trials, that could help at this stage, and how soon would we need to decide?
  3. 3.Should brothers, sisters or other relatives be tested, and what are our options in a future pregnancy?
  4. 4.Who should be part of the care team, and how will we manage seizures, feeding and mobility as needs change?

Last reviewed • Oct 2026

Educational content, not medical advice.